Omformin may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Omformin in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Deep Vein Thrombosis, Recurrent Event. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Micromedex Care Notes:
Medical Encyclopedia:
Oxilepsi may be available in the countries listed below.
Oxcarbazepine is reported as an ingredient of Oxilepsi in the following countries:
International Drug Name Search
Generic Name: Bepotastine Besilate
Class: Antiallergic Agents
Chemical Name: 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-,benzene sulfonate (1:1); (2) (+)-4-{4-[(S)-(4-Chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid monobenzenesulfonate.
Molecular Formula: C21H25ClN2O3.C6H6O3S.547.10
CAS Number: 190786-44-8
Histamine H 1-receptor antagonist with mass-cell stabilizing activity.1 2 3 5
Symptomatic treatment of ocular itching associated with allergic conjunctivitis.1 3 7 8 9 10
Apply topically to the eye as an ophthalmic solution.1 2 3 5 6
Remove soft contact lenses prior to administration of each dose (since benzalkonium chloride may be absorbed by the lenses); may reinsert lenses after 10 minutes following administration if eyes are not red.1 5
Avoid contamination of the solution container.1 5
Available as bepotastine besilate; dosage expressed in terms of the salt.1
Children ≥2 years of age: 1 drop of a 1.5% solution in the affected eye(s) twice daily.1
1 drop of a 1.5% solution in the affected eye(s) twice daily.1 5
Manufacturer states none known.1
For topical ophthalmic use only.1
To avoid contamination of the dropper tip and solution, do not to touch the eyelids or surrounding areas with the dropper tip.1
Close container tightly when not in use.1
Remove contact lenses prior to administration of each dose, since benzalkonium chloride preservative may be absorbed by soft contact lenses; lenses may be reinserted after 10 minutes following administration if eyes are not red; patient should not wear contact lenses if eyes are red.1 5 Not indicated for contact lens-related ocular irritation.1 5
Category C.1 5
Distributed into milk in rats following oral administration.1
Not known whether bepotastine besilate distributes into human milk following topical application to the eye.1 Use caution.1
Safety and efficacy not established in pediatric patients <2 years of age.1 Efficacy in pediatric patients <10 years of age was extrapolated from clinical trials conducted in pediatric patients >10 years of age and adults.1
No overall differences in efficacy or safety observed between geriatric and younger patients.1
Mild taste following instillation,1 3 6 ocular irritation, headache, nasopharyngitis.1 2 3 10
Minimally metabolized by CYP isoenzymes.1
Low potential for drug interactions via inhibition of CYP isoenzymes 3A4, 2C9, and 2C19.1
Effect on metabolism of substrates of CYP isoenzymes 1A2, 2C8, and 2D6 not established.1
Peak plasma concentrations achieved approximately 1–2 hours after instillation.1
Approximately 55%.1
Minimally metabolized by CYP isoenzymes.1
Excreted principally in urine as unchanged drug (75–90%).1
15–25°C.1
Inhibits the release of histamine and other mediators (e.g., leukotrienes, platelet activating factor [PAF]) involved in allergic reactions.1 2 3 5
Exhibits mast-cell stabilizing activity.1 2 3 5
Inhibits eosinophil migration to and activation at inflammatory sites.2
Importance of learning and adhering to proper administration techniques to avoid contamination of the solution.1 5
Importance of removing contact lenses prior to administration of each ophthalmic dose, since benzalkonium chloride preservative may be absorbed by soft lenses; may reinsert contact lenses after 10 minutes following administration if eyes are not red; importance of not wearing contact lenses if eyes are red.1 5
Not indicated for contact lens-related ocular irritation.1 5
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information.
(See Cautions.)1
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Ophthalmic | Solution | 1.5% | Bepreve | Ista |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Bepreve 1.5% Solution (ISTA PHARMACEUTICALS): 10/$189.98 or 30/$529.97
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Ista Pharmaceuticals. Bepreve(bepotastine besilate) ophthalmic solution prescribing information. Irvine, CA; 2009 Aug. (
2. Abelson MB, Torkildsen GL, Williams JI et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solution 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009; 31:1908-21. [PubMed 19843481]
3. Anon. Bepotastine (Bepreve)—An ophthalmic H1 antihistamine. Med Lett. 2010; 52:8-12.
4. Protzko EE, Gomes PJ, Williams JI et al. The ocular comfort and safety of the novel anti-Histamine bepotastine besilate ophthalmic solution 1.5% in a healthy pediatric population. J Allergy Clin Immunol. 2009; (Suppl 2): S50.
5. Hussar DA, Abbas CA. New drugs: asenapine, iloperidone, and bepotastine besilate. J Am Pharm Assoc. 2010; 50:107-10.
6. Gow JA, Protzko EE, Gomes PJ et al. Safety of the antihistamine bepotastine besilate ophthalmic solution in a healthy pediatric population from 3 to 9 years of age. Poster presented at: 35th Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery. San Francisco, CA: 2009 April 4-8. Abstract 559458.
7. Meier EJ, Macejko TT, Bergmann MT et al. Bepotastine besilate ophthalmic solution 1.0% provides rapid relief of rhinorrhea, total non-ocular symptoms, tearing, and ciliary and episcleral hyperemia following dosing in a multi-site clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl): S57.
8. Torkildsen GL, Gomes PJ, Williams JI et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl): S57.
9. Macejko TT, Meier EJ, Bergmann MT et al. Bepotastine besilate ophthalmic solution 1.5% for up to 8 hours following dosing reduces total non-ocular symptoms, rhinorrhea, and tearing in a multi-site clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009; 123 (Suppl):S57.
10. Bergmann MT, Gomes PJ, Williams JI et al. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a multisite clinical model of allergic conjunctivitis. Poster presented at the 35th Symposium on Cataract, IOL, and Refractive Surgery of the American Society of Cataract and Refractive Surgery. San Francisco, CA: 2009 April 4-8. Abstract 559520.
11. ISTA Pharmaceuticals, Irvine, CA: Personal communication.
12. Wadhwa SD. Medical review(s) for bepotastine besilate ophthalmic solution 1.5% (Bepreve), application number 22-228. Rockville, MD: US Food and Drug Administration; 2009 Apr 27. From FDA website ().
Otofluor may be available in the countries listed below.
Calcium Gluconate is reported as an ingredient of Otofluor in the following countries:
Sodium Fluoride is reported as an ingredient of Otofluor in the following countries:
International Drug Name Search
In the US, Chibroxin (norfloxacin ophthalmic) is a member of the drug class ophthalmic anti-infectives and is used to treat Conjunctivitis and Ophthalmic Surgery.
US matches:
Norfloxacin is reported as an ingredient of Chibroxin in the following countries:
International Drug Name Search
Dolomolargesico may be available in the countries listed below.
Paracetamol is reported as an ingredient of Dolomolargesico in the following countries:
International Drug Name Search
Oméprazole RPG may be available in the countries listed below.
Omeprazole is reported as an ingredient of Oméprazole RPG in the following countries:
International Drug Name Search
Orbenil may be available in the countries listed below.
Cloxacillin is reported as an ingredient of Orbenil in the following countries:
International Drug Name Search
Hemorif may be available in the countries listed below.
Diosmin is reported as an ingredient of Hemorif in the following countries:
International Drug Name Search
Beytina may be available in the countries listed below.
Dihydroergocristine mesilate (a derivative of Dihydroergocristine) is reported as an ingredient of Beytina in the following countries:
International Drug Name Search
Generic Name: belladonna, ergotamine, and phenobarbital (bel uh DON uh, er GOT uh meen, and feen oh BAR bit al)
Brand Names: Bel-Phen-Ergot, Bellamine, Bellamor, Bellaphen-S, Bellaspas, Bellergal-S, Duragal-S, Eperbel-S, Spastrin
Belladonna is a naturally occurring mixture that produces many effects in the body. It reduces spasms within the stomach and intestines, the bladder, and the biliary (liver) system. Belladonna also reduces the secretions of many organs, which helps control conditions such as excess stomach acid.
Ergotamine narrows the blood vessels involved in circulation to the head. Ergotamine can also alter blood flow patterns involved in vascular headaches, such as migraines.
Phenobarbital is a barbiturate that reduces brain and nervous system activity.
The combination of belladonna, ergotamine, and phenobarbital is used to treat symptoms of menopause including hot flashes, sweating, increased heart rate, dizziness, restlessness, headache, anxiety, and trouble sleeping.
Belladonna, ergotamine, and phenobarbital may also be used for purposes other than those listed in this medication guide.
Avoid using other medicines that make you sleepy (such as cold medicine, pain medication, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by belladonna, ergotamine, and phenobarbital.
narrow-angle glaucoma;
heart disease;
liver disease;
kidney disease;
porphyria;
a history of circulation problems, stroke, or blood clots;
high blood pressure; or
if you are pregnant or breast-feeding.
Before using belladonna, ergotamine, and phenobarbital, tell your doctor if you have:
a stomach problem called pyloric obstruction; or
angina (chest pain).
If you have any of these conditions, you may not be able to use this medication, or you may need a dosage adjustment or special tests during treatment.
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor.
To be sure this medication is helping your condition, your doctor may need to check your progress on a regular basis. It is important that you not miss any scheduled visits to your doctor.
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take extra medicine to make up the missed dose.
Avoid using other medicines that make you sleepy (such as cold medicine, pain medication, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by belladonna, ergotamine, and phenobarbital.
Other less serious side effects are more likely to occur, such as:
blurred vision;
dry mouth;
warmth or tingly feeling;
drowsiness; or
changes in behavior (in children).
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Before taking this medication, tell your doctor if you are using any of the following drugs:
a blood thinner such as warfarin (Coumadin);
birth control pills;
erythromycin (E-Mycin, Ery-Tab, Erythrocin, E.E.S.); or
troleandomycin (Tao).
If you are using any of these drugs, you may not be able to use belladonna, ergotamine, and phenobarbital, or you may need dosage adjustments or special tests during treatment.
There may be other drugs not listed that can affect belladonna, ergotamine, and phenobarbital. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
Belladonna, ergotamine, and phenobarbital is available with a prescription under the brand names Bellergal, Bellamine, Bellaspas, Duragal-S, and Spastrin. Other brand or generic forms may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
In the US, Niaspan (niacin systemic) is a member of the following drug classes: miscellaneous antihyperlipidemic agents, vitamins and is used to treat High Cholesterol, Hyperlipoproteinemia, Hyperlipoproteinemia Type IV - Elevated VLDL and Hyperlipoproteinemia Type V - Elevated Chylomicrons VLDL.
US matches:
UK matches:
Nicotinic Acid is reported as an ingredient of Niaspan in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Anadin may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Anadin in the following countries:
International Drug Name Search
Algicler may be available in the countries listed below.
Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Algicler in the following countries:
International Drug Name Search
